Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

First Posted Date
2013-11-14
Last Posted Date
2020-01-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
61
Registration Number
NCT01983969
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

First Posted Date
2013-10-25
Last Posted Date
2017-05-09
Lead Sponsor
University of Louisville
Registration Number
NCT01969942
Locations
🇺🇸

Pediatric Hematology/Oncology University of Louisville, Louisville, Kentucky, United States

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

First Posted Date
2013-10-11
Last Posted Date
2024-02-22
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
3
Registration Number
NCT01961063
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

First Posted Date
2013-10-10
Last Posted Date
2015-08-13
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
33
Registration Number
NCT01959477
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

First Posted Date
2013-09-24
Last Posted Date
2024-01-16
Lead Sponsor
St. Anna Kinderkrebsforschung
Target Recruit Count
1800
Registration Number
NCT01949129
Locations
🇦🇷

Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Argentina

🇧🇪

University Hospitals Leuven Kinderhemato-oncologie, Leuven, Belgium

🇮🇱

Dana Children's Hospital, Tel Aviv, Israel

and more 115 locations

Therapy for Children With Advanced Stage Neuroblastoma

First Posted Date
2013-05-20
Last Posted Date
2024-12-19
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
153
Registration Number
NCT01857934
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

First Posted Date
2013-05-13
Last Posted Date
2022-08-03
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
46
Registration Number
NCT01852071
Locations
🇺🇸

Mattel Children's Hospital, UCLA, Los Angeles, California, United States

🇺🇸

Mark O. Hatfield Clinical Research Center, NIH, Bethesda, Maryland, United States

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

First Posted Date
2013-04-05
Last Posted Date
2018-12-05
Lead Sponsor
Children's Oncology Group
Target Recruit Count
30
Registration Number
NCT01824693
Locations
🇺🇸

Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

🇺🇸

Mattel Children's Hospital UCLA, Los Angeles, California, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 47 locations

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

First Posted Date
2013-04-04
Last Posted Date
2023-11-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
63
Registration Number
NCT01823198
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

First Posted Date
2013-02-25
Last Posted Date
2024-07-15
Lead Sponsor
Children's Oncology Group
Target Recruit Count
150
Registration Number
NCT01798004
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

🇺🇸

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 120 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy